How is [Rituxan] different than any other non-interchangeable FoB?
It’s different only insofar as Rituxan was targeted by several FoB companies and partnerships, reducing the prospects for all of them. More generally, non-interchangeable FoB’s are going to be a tough business proposition, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”